These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 18473686)

  • 1. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
    Worgall S; Sondhi D; Hackett NR; Kosofsky B; Kekatpure MV; Neyzi N; Dyke JP; Ballon D; Heier L; Greenwald BM; Christos P; Mazumdar M; Souweidane MM; Kaplitt MG; Crystal RG
    Hum Gene Ther; 2008 May; 19(5):463-74. PubMed ID: 18473686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
    Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
    Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
    Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
    Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
    Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
    Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
    Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Peterson DA; Edelstein AM; del Fierro K; Hackett NR; Crystal RG
    Exp Neurol; 2008 Sep; 213(1):18-27. PubMed ID: 18639872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
    Sondhi D; Hackett NR; Peterson DA; Stratton J; Baad M; Travis KM; Wilson JM; Crystal RG
    Mol Ther; 2007 Mar; 15(3):481-91. PubMed ID: 17180118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.
    Worgall S; Kekatpure MV; Heier L; Ballon D; Dyke JP; Shungu D; Mao X; Kosofsky B; Kaplitt MG; Souweidane MM; Sondhi D; Hackett NR; Hollmann C; Crystal RG
    Neurology; 2007 Aug; 69(6):521-35. PubMed ID: 17679671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
    Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
    J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
    Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
    Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
    Cabrera-Salazar MA; Roskelley EM; Bu J; Hodges BL; Yew N; Dodge JC; Shihabuddin LS; Sohar I; Sleat DE; Scheule RK; Davidson BL; Cheng SH; Lobel P; Passini MA
    Mol Ther; 2007 Oct; 15(10):1782-8. PubMed ID: 17637720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing
    Sondhi D; Kaminsky SM; Hackett NR; Pagovich OE; Rosenberg JB; De BP; Chen A; Van de Graaf B; Mezey JG; Mammen GW; Mancenido D; Xu F; Kosofsky B; Yohay K; Worgall S; Kaner RJ; Souwedaine M; Greenwald BM; Kaplitt M; Dyke JP; Ballon DJ; Heier LA; Kiss S; Crystal RG
    Sci Transl Med; 2020 Dec; 12(572):. PubMed ID: 33268510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models.
    Sohar I; Sleat DE; Jadot M; Lobel P
    J Neurochem; 1999 Aug; 73(2):700-11. PubMed ID: 10428067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
    Sleat DE; El-Banna M; Sohar I; Kim KH; Dobrenis K; Walkley SU; Lobel P
    Mol Genet Metab; 2008 Jun; 94(2):222-33. PubMed ID: 18343701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis.
    Sondhi D; Hackett NR; Apblett RL; Kaminsky SM; Pergolizzi RG; Crystal RG
    Arch Neurol; 2001 Nov; 58(11):1793-8. PubMed ID: 11708986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal testing for late infantile neuronal ceroid lipofuscinosis.
    Berry-Kravis E; Sleat DE; Sohar I; Meyer P; Donnelly R; Lobel P
    Ann Neurol; 2000 Feb; 47(2):254-7. PubMed ID: 10665500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene.
    Hartikainen JM; Ju W; Wisniewski KE; Moroziewicz DN; Kaczmarski AL; McLendon L; Zhong D; Suarez CT; Brown WT; Zhong N
    Mol Genet Metab; 1999 Jun; 67(2):162-8. PubMed ID: 10356316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exclusion of late infantile neuronal ceroid lipofuscinosis (LINCL) in a fetus by assay of tripeptidyl peptidase I in chorionic villi.
    Young EP; Winchester BG; Peter Logan W; Wheeler RB; Lake BD
    Prenat Diagn; 2000 Apr; 20(4):337-9. PubMed ID: 10740208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations.
    Souweidane MM; Fraser JF; Arkin LM; Sondhi D; Hackett NR; Kaminsky SM; Heier L; Kosofsky BE; Worgall S; Crystal RG; Kaplitt MG
    J Neurosurg Pediatr; 2010 Aug; 6(2):115-22. PubMed ID: 20672930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.